These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 8234542

  • 21. Fibrinolytic activity in retinal vein occlusion.
    Abu El-Asrar AM, Abdel Gader AG, Al-Amro S, Al-Momem AK.
    Int Ophthalmol; ; 21(6):343-8. PubMed ID: 9869344
    [Abstract] [Full Text] [Related]

  • 22. Relationship of plasminogen activator inhibitor-1 with plasma insulin, glucose, triglyceride and cholesterol in Chinese patients with diabetes.
    Ho CH, Jap TS.
    Thromb Res; 1993 Feb 01; 69(3):271-7. PubMed ID: 8475477
    [Abstract] [Full Text] [Related]

  • 23. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H, Suzuki Y, Sano H, Suda T, Chida K, Dan T, Miyata T, Urano T.
    Thromb Res; 2013 Jul 01; 132(1):100-5. PubMed ID: 23611258
    [Abstract] [Full Text] [Related]

  • 24. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
    Iwan-Zietek I, Zietek Z, Kotschy M, Rość D, Tyloch F.
    Pol Tyg Lek; 1996 Feb 01; 51(6-9):91-3. PubMed ID: 8756741
    [Abstract] [Full Text] [Related]

  • 25. Fibrinolytic activity in patients with idiopathic and secondary deep venous thrombosis.
    Harbourne T, O'Brien D, Nicolaides AN.
    Thromb Res; 1991 Dec 01; 64(5):543-50. PubMed ID: 1808759
    [Abstract] [Full Text] [Related]

  • 26. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
    Colucci M, Altomare DF, Chetta G, Triggiani R, Cavallo LG, Semeraro N.
    Thromb Haemost; 1988 Aug 30; 60(1):25-9. PubMed ID: 3142090
    [Abstract] [Full Text] [Related]

  • 27. [Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes].
    Rość D, Drewniak W, Kotschy M, Graczykowska-Koczorowska A, Raukuć D.
    Pol Merkur Lekarski; 1997 Jan 30; 2(7):24-5. PubMed ID: 9296893
    [Abstract] [Full Text] [Related]

  • 28. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM, Greco WR.
    Cancer Res; 1986 Apr 30; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [Abstract] [Full Text] [Related]

  • 29. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
    Stegnar M, Zore A, Novak-Antolic Z, Vovk N, Kruithof EK.
    Thromb Haemost; 1993 Sep 01; 70(3):486-90. PubMed ID: 8259554
    [Abstract] [Full Text] [Related]

  • 30. Sex differences in the determinants of fibrinolytic activity.
    MacCallum PK, Cooper JA, Howarth DJ, Meade TW, Miller GJ.
    Thromb Haemost; 1998 Mar 01; 79(3):587-90. PubMed ID: 9531046
    [Abstract] [Full Text] [Related]

  • 31. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA, Gálvez MM, Cornudella R, Angós JA, Romero MS, Gutiérrez M.
    Sangre (Barc); 1994 Apr 01; 39(2):111-6. PubMed ID: 8059288
    [Abstract] [Full Text] [Related]

  • 32. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov 01; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 33. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA.
    Thromb Haemost; 1996 Sep 01; 76(3):422-8. PubMed ID: 8883281
    [Abstract] [Full Text] [Related]

  • 34. Euglobulin lysis times: an update.
    Glassman A, Abram M, Baxter G, Swett A.
    Ann Clin Lab Sci; 1993 Sep 01; 23(5):329-32. PubMed ID: 8239479
    [Abstract] [Full Text] [Related]

  • 35. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis?
    Glueck CJ, Glueck HI, Mieczkowski L, Tracy T, Speirs J, Stroop D.
    Thromb Haemost; 1993 May 03; 69(5):460-5. PubMed ID: 8322268
    [Abstract] [Full Text] [Related]

  • 36. Relation between dietary and circulating lipids in lacto-ovo vegetarians.
    Fernandes Dourado K, de Arruda Cámara E Siqueira Campos F, Sakugava Shinohara NK.
    Nutr Hosp; 2011 May 03; 26(5):959-64. PubMed ID: 22072338
    [Abstract] [Full Text] [Related]

  • 37. Fibrinolytic defect in chronic back pain. A controlled study of plasminogen activator activity in 20 patients.
    Hurri HO, Petäjä JM, Alaranta HT, Landtman MC, Soini JR, Vahtera EM, Laitinen HI.
    Acta Orthop Scand; 1991 Oct 03; 62(5):407-9. PubMed ID: 1835242
    [Abstract] [Full Text] [Related]

  • 38. Haematological, biochemical and bone density parameters in vegetarians and non-vegetarians.
    Sambol SZ, Stimac D, Orlić ZC, Guina T.
    West Indian Med J; 2009 Dec 03; 58(6):512-7. PubMed ID: 20583676
    [Abstract] [Full Text] [Related]

  • 39. Influence of hysterectomy on the fibrinolytic activity of plasma of women with intact ovarian function.
    Schubring C, Grulich-Henn J, Bauer S, Gips H, Müller-Berghaus G.
    Eur J Obstet Gynecol Reprod Biol; 1995 Mar 03; 59(1):39-43. PubMed ID: 7781859
    [Abstract] [Full Text] [Related]

  • 40. Changes of the fibrinolytic system of animals induced by injection of tissue plasminogen activator.
    Andreenko GV, Lyutova LV, Shimonaeva EE.
    Thromb Res; 1982 Aug 01; 27(3):279-88. PubMed ID: 6215740
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.